Michael Vodicka, Licensed Investment Advisor, does the research and tells
members exactly which cannabis stocks he’s buying and selling in his model portfolio.
We make finding the right cannabis stocks simple.
As a member of Cannabis Stock Trades, you'll have total and transparent access to a professionally managed model cannabis portfolio.
Most people don't have the time to thoroughly research cannabis stocks, nor the experience to know when to buy or sell.
Cash in on this incredible opportunity with the guidance of a professional advisor and leading cannabis stock expert.
Michael Vodicka is a licensed investment advisor, founder of a million-dollar wealth management firm and a globally syndicated financial journalist. He, and his wealth management clients, have been profiting from cannabis stocks since 2013.
Now Mr. Vodicka brings this experience and guidance to the members of Cannabis Stock Trades.
June 26 was a groundbreaking day for the US cannabis industry.
That’s the day the FDA, the US agency responsible for approving new drug candidates, approved its first-ever cannabis drug.
The first-ever medical treatment derived from a marijuana plant will hit the U.S. market in a few months after regulators on Monday gave the epilepsy treatment the green light. Continue “Promising Cannabis Biotech Jumps 23% on Great FDA News”
October 30, 2017 was one of the best days of the year for the young cannabis industry.
That’s the date when Constellation Brands (NYSE: STZ), the second-largest US beer maker, announced a 10% stake in Canopy Growth (NYSE: CGC), the largest Canadian cannabis company.
It was a groundbreaking moment for the cannabis industry because it was the first time that a big alcohol company had invested directly in a cannabis company. Continue “2 Early Canadian Leaders Ready to Soar on Buyout Rumors”
Germany has quickly emerged as one of the fastest-growing medical cannabis markets in the world.
According to a study on the German health insurance market, 500 German patients requested medical cannabis in January of 2017.
In December of the same year, the number of patients requesting reimbursements for cannabis prescriptions skyrocketed to 13,000.
What was the biggest factor that drove the huge spike? Continue “New Entry into Germany’s Cannabis Industry up 475% in 12 Months”